Phase II pilot trial of autologous cell therapy utilising tumour infiltrating lymphocytes [Contego] in patients with ovarian cancer.
Phase of Trial: Phase II
Latest Information Update: 13 Oct 2011
At a glance
- Drugs LN 144 (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions; Therapeutic Use
- 13 Oct 2011 Status changed from not stated to planning.
- 13 Oct 2011 New trial record